Pharmacological inhibition of leukotriene biosynthesis: Effects on the heart conductance

Journal of Physiology and Pharmacology

Volumn 61, Issue 1, 2010, Pages 53-58

  Sanak, M ^a   Dropinski, J ^a   Sokolowska, B ^a   Faber, J ^a   Rzeszutko, M ^a   Szczeklik, Andrzej ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

5 lipoxygenase; Conductance system; Coronary arteries disease; Heart rate variability; Leukotrienes

Indexed keywords

C REACTIVE PROTEIN; LEUKOTRIENE; LEUKOTRIENE E4; LIPOXYGENASE; PLACEBO; ZILEUTON; ARACHIDONATE 5 LIPOXYGENASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR;

ADULT; ANGIOCARDIOGRAPHY; ARTERY CATHETERIZATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ELECTIVE SURGERY; ELECTROCARDIOGRAM; ENZYME INHIBITION; FEMALE; HEART CONDUCTION; HEART RATE VARIABILITY; HEART REPOLARIZATION; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROSTAGLANDIN SYNTHESIS; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT DEPRESSION; STABLE ANGINA PECTORIS; TRANSLUMINAL CORONARY ANGIOPLASTY; URINALYSIS; AGED; ANGINA, UNSTABLE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG EFFECTS; ENZYMOLOGY; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; URINE;

AGED; ANGINA, UNSTABLE; ARACHIDONATE 5-LIPOXYGENASE; DOUBLE-BLIND METHOD; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENE E4; LEUKOTRIENES; LIPOXYGENASE INHIBITORS; MALE; MIDDLE AGED;

EID: 77954246286     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220: 568-575.
2. Peters-Golden M, Henderson WR Jr. Leukotrienes. N Engl J Med 2007; 357: 1841-1854.
3. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006; 58: 375-388.
4. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J Immunol 2004; 173: 1503-1510.
5. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation 1998; 97: 2406-2413.
6. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-1243.
7. Qiu H, Gabrielsen A, Agardh HE, et al. Expression of 5- lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc Natl Acad Sci USA 2006; 103: 8161-8166.
8. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-239.
9. Zee RY, Cheng S, Hegener HH, Erlich HA, Ridker PM. Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke 2006; 37: 2007-2011.
10. Iovannisci DM, Lammer EJ, Steiner L, et al. Association between a leukotriene C4 synthase gene promoter polymorphism and coronary artery calcium in young women: the Muscatine Study. Arterioscler Thromb Vasc Biol 2007; 27: 394-399.
11. Loscalzo J. Association studies in an era of too much information: clinical analysis of new biomarker and genetic data. Circulation 2007; 116: 1866-1870.
12. Dahlen B, Nizankowska E, Szczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998; 157: 1187-1194.
13. O'Connor BJ, Lofdahl CG, Balter M, Szczeklik A, Boulet LP, Cairns CB. Zileuton added to low-dose inhaled beclomethasone for the treatment of moderate to severe persistent asthma. Respir Med 2007; 101: 1088-1096.
14. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126: 177-183.
15. American Lung Association Asthma Clinical Research Centers, Peters SP, Anthonisen N, Castro M, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356: 2027-2039.
16. Rossoni G, Sala A, Berti F, et al. Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J Pharmacol Exp Ther 1996; 276: 335-341.
17. Gok S, Ulker S, Huseinov A, Evinc A. Effects of a lipoxygenase inhibitor on digoxin-induced cardiac arrhytmias in the isolated perfused guinea-pig heart. Gen Pharmac 1997; 29: 789-792.
18. Gok S, Ulker S, Evinc A. Possible contribution of leukotrienes in the arrhytmogenic effects of digoxin on isloated guinea-pig hearts. Pharmacology 1998; 57: 279-284.
19. Jawien J, Gajda M, Rudling M, et al. Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006; 36: 141-146.
20. Allen SP, Sampson AP, Piper PJ, Chester AH, Ohri SK, Yacoub MH. Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery. Coron Artery Dis 1993; 4: 899-904.
21. Carry M, Korley V, Willerson JT, Weigelt L, Ford-Hutchinson AW, Tagari P. Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation 1992; 85: 230-236.
22. Szczeklik A, Nizankowska E, Mastalerz L, Bochenek G. Myocardial ischemia possibly mediated by cysteinyl leukotrienes. J Allergy Clin Immunol 2002; 109: 572-573.
23. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggers intracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 1992; 86: 56-63.
24. Rzeszutko M, Karczmarek P, Nowakowski T, et al. Percutaneous coronary intervention is associated with overproduction of cysteinyl leukotrienes. Eur Heart J 2006; 27(Suppl). 227.
25. Evans JF. Cysteinyl leukotriene receptors. Prostaglandins Other Lipid Mediat 2002; 68-69: 587-597.
26. Hui Y, Cheng Y, Smalera I, et al. Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 2004; 110: 3360-3366.
27. Hahn RA, MacDonald BR, Simpson PJ, et al. Characterization of LY233569 on 5-lipoxygense and reperfusion injury of ischemic myocardium. J Pharmacol Exp Ther 1991; 256: 94-102.
28. Adamek A, Jung S, Dienesch C, et al. Role of 5-lipoxygenase in myocardial ischemia-reperfusion injury in mice. Eur J Pharmacol 2007; 571: 51-54.
29. Toki Y, Hieda N, Torii T, et al. The effects of lipoxygenase inhibitor and peptidoleukotriene antagonist on myocardial injury in a canine coronary occlusion reperfusion model. Prostaglandins 1988; 35: 555-571.
30. Hahn RA, MacDonald BR, Simpson PJ, Potts BD, Parli CJ. Antagonism of leukotriene B4 receptors does not limit canine myocardial infarct size. J Pharmacol Exp Ther 1990; 253: 58-66.
31. Mastalerz L, Sanak M, Szczeklik A. Pharmacological inhibitors of cysteinyl leukotrienes biosynthesis: therapeutic implications. Cur Med Chem 2004; 3: 157-165.
32. Walch L, Norel X, Gascard JP, Brink C. Functional studies of leukotriene receptors in vascular tissues. Am J Respir Crit Care Med 2000; 161: S107-S11.
33. Ciana P, Fumagalli M, Trincavelli ML, et al. The orphan receptor GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes receptor. EMBO J 2006; 25: 4615-4627.
34. Foller M, Mahmud H, Hu S, et al. Participation of leukotriene C4 in the regulation of suicidal erythrocyte death. J Physiol Pharmacol 2009; 60: 135-143.
35. Jiang W, Hall SR, Moos MP, et al. Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am J Pathol 2008; 172: 592-602.
36. Malik M. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Eur Heart J 1996; 17: 354-381.
37. Taylor JA, Carr DL, Myers CW, Eckberg DL. Mechanisms underlying very-low-frequency oscillations in humans. Circulation 1998; 98: 547-555.
38. La Rovere MT, Pinna GD, Maestri R, et al. Short-term heart rate variability strongly predicts sudden cardiac death in chronic heart failure patients. Circulation 2003; 107: 565-570.
39. Kurachi Y, Ito H, Sugimoto T, Shimizu T, Miki I, Ui M. Arachidonic acid metabolites as intracellular modulators of the G protein-gated cardiac K+ channel. Nature 1989; 337: 555-557.
40. Kim D, Lewis DL, Graziadei L, Neer EJ, Bar-Sagi G, Clapham DE. G-protein bg-subunits activate the cardiac muscarinic K+-channel via phospholipse A2. Nature 1989; 337: 557-560.